These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22211798)

  • 1. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
    Hayashi Y; Nakamae H; Katayama T; Nakane T; Koh H; Nakamae M; Hirose A; Hagihara K; Terada Y; Nakao Y; Hino M
    Leuk Lymphoma; 2012 Jun; 53(6):1084-9. PubMed ID: 22211798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
    Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
    Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
    J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
    Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
    Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
    Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
    J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
    Erba HP; Pham DC; Zaiden R; Vu H; Tai S
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
    Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
    Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
    Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
    Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
    Gruber FX; Ernst T; Porkka K; Engh RA; Mikkola I; Maier J; Lange T; Hochhaus A
    Leukemia; 2012 Jan; 26(1):172-7. PubMed ID: 21818112
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.